✦ LIBER ✦

Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia

✍ Scribed by Williams, C. ;Whitehouse, J. M. A. ;Lister, T. A. ;Wrigley, P. F. M.

Publisher: John Wiley and Sons
Year: 1977
Tongue: English
Weight: 315 KB
Volume: 3
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.2950030309

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Fifty‐six untreated patients with acute leukemia (38 acute myelogenous leukemia, 16 acute lymphoblastic leukemia, and 2 blast crisis of chronic granulocytic leukemia) were randomized on admission to one of three groups – one to receive oral anticandidal prophylaxis through the period of remission induction chemotherapy with nystatin, another to receive natamycin, and the third to receive no anticandidal prophylaxis.

Neither of the first two groups show any advantage over the last and it is concluded that provided gut sterilization regimes are not employed, prophylactic oral anticandidal treatment is of no value in these patients and should be reserved until there is clinical evidence of infection.

📜 SIMILAR VOLUMES

Intravenous itraconazole for prophylaxis

Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy

✍ Gloria N. Mattiuzzi; Hagop Kantarjian; Susan O'Brien; Dimitrios P. Kontoyiannis; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## BACKGROUND Systemic fungal infections remain the leading cause of mortality in patients with newly diagnosed acute myelogenous leukemia (AML) and high‐risk myelodysplastic syndrome (MDS). The objective of the current study was to determine whether intravenous itraconazole (I.V. ITRA

Hepatitis B prophylaxis in patients unde

Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model

✍ Sammy Saab; Mamie H. Dong; Tom A. Joseph; Myron J. Tong 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB

Hepatitis B reactivation is a major cause of morbidity and mortality in patients undergoing chemotherapy for lymphomas. These patients may experience direct liver-related complications or reduced cancer survival because of interruptions in chemotherapy. Our aim was to compare the costs and outcomes

Amphotericin B lipid complex as prophyla

Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy

✍ Gloria N. Mattiuzzi; Hagop Kantarjian; Stefan Faderl; JoAnn Lim; Dimitrios Konto 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

## Abstract ## BACKGROUND The optimal antifungal prophylactic regimen for patients with acute myelogenous leukemia (AML) or high‐risk myelodysplastic syndrome (MDS) undergoing induction chemotherapy has yet to be identified. A prospective historical control study evaluated the efficacy and safety

Thiamine deficiency in a patient receivi

Thiamine deficiency in a patient receiving chemotherapy for acute myeloblastic leukemia

✍ Ulusakarya, Ayhan; Vantelon, Jean-Marie; Munck, Jean-Nicolas; Fenaux, Pierre; Re 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

Multiple-drug chemotherapy for acute leu

Multiple-drug chemotherapy for acute leukemia. The TRAMPCOL regimen: Results in 86 patients

✍ A. S. D. Spiers; J. M. Goldman; D. Catovsky; Christine Costello; N. A. Buskard; 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 888 KB

A combination of eight cytotoxic drugs, administered simultaneously, has been used in 86 cases of acute leukemia. The regimen, designated TRAMPCOL, incorporated thioguanine, rubidomycin, (daunorubicin), ytosine arabinoside, methotrexate, prednisolone, cyclophosphamide, vincristine, and usually Laspa

Low-dose combination chemotherapy for ac

Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: A novel approach

✍ Manoharan, Arumugam; Baker, Ross I.; Kyle, Peter W. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 27 KB 👁 2 views

Eighteen patients aged 60-84 years with acute myeloid leukemia were treated with lowdose combination chemotherapy comprising cytarabine, etoposide, and mitozantrone or 6-thioguanine; seven of these patients had a pre-existing myelodysplastic syndrome. Nine patients achieved a complete remission, and